EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Receptor-Mediated Drug Delivery: Redefining Targeted Drug Conjugates in Oncology

Keon Niles Jafari iD, Charlene Chai, Shelby Kim, Kamaljit Kaur iD

Pharmaceutics · 20.03.2026 · 18 (3) · 386

DOI: 10.3390/pharmaceutics18030386 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pharmaceutics, online erschienen am 20.03.2026. Verfasst von Keon Niles Jafari und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical and Pharmaceutical Sciences, School of Pharmacy, Harry and Diane Rinker Health Science Campus, Chapman University, Irvine, C…. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 85 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, National Cancer Institute of the National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Targeted drug delivery (TDD), specifically through targeting ligand–drug conjugates, has reshaped oncology by enabling selective delivery of cytotoxic payloads to cancer cells while minimizing uptake by normal tissues. A key approach relies on exploiting overexpressed cell surface receptors (CSRs) to enable selective uptake of drug conjugates via receptor-mediated endocytosis. This review delineates four clinically validated CSRs (HER2, Trop-2, Nectin-4, and SSTR2) with several FDA-approved drug conjugates. Furthermore, emerging CSRs (EGFR, DLL3, and keratin 1) that may support next-generation TDD platforms for cancer treatment are also highlighted. We discuss how CSR type, density on cancer cells, and its mechanism of endocytosis, as well as the conjugate design for cellular uptake, tissue distribution, ligand size, and linker stability, collectively determine tumor drug accumulation and therapeutic efficacy. From representative examples, we elucidate the rationale for judicious refinement of these parameters, guiding the development of more potent ligands and drug conjugates to enhance the therapeutic efficacy of cytotoxic agents.

Schlagwörter

Stichwörter der Autor:innen

cell surface receptorsdrug conjugatesoverexpressiontargeted drug deliverytumor drug concentration

Autor:innen und Institutionen

  • Department of Biomedical and Pharmaceutical Sciences, School of Pharmacy, Harry and Diane Rinker Health Science Campus, Chapman University, Irvine, CA 92618, USA.
  • Center for Targeted Drug Delivery (CTDD), School of Pharmacy, Chapman University, Irvine, CA 92618, USA.
  • Schmid College of Science and Technology, Chapman University, Orange, CA 92866, USA.

ORCID-Profile: Keon Niles Jafari, Kamaljit Kaur

Förderung

  • NCI NIH HHS
  • National Cancer Institute of the National Institutes of Health

Zitieren

APA

Jafari, K. N., Chai, C., Kim, S., & Kaur, K. (2026). Receptor-Mediated Drug Delivery: Redefining Targeted Drug Conjugates in Oncology. Pharmaceutics, 18(3), 386. https://doi.org/10.3390/pharmaceutics18030386

Vancouver

Jafari KN, Chai C, Kim S, Kaur K. Receptor-Mediated Drug Delivery: Redefining Targeted Drug Conjugates in Oncology. Pharmaceutics. 2026;18(3):386. doi:10.3390/pharmaceutics18030386

BibTeX
@article{Jafari2026,
  author = {Jafari, Keon Niles and Chai, Charlene and Kim, Shelby and Kaur, Kamaljit},
  title = {Receptor-Mediated Drug Delivery: Redefining Targeted Drug Conjugates in Oncology},
  journal = {Pharmaceutics},
  year = {2026},
  volume = {18},
  number = {3},
  pages = {386},
  doi = {10.3390/pharmaceutics18030386}
}
Kostenlos starten →